Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis
Background To date, more than 761 million confirmed SARS-CoV-2 infections have been
recorded globally, and more than half of all children are estimated to be seropositive …
recorded globally, and more than half of all children are estimated to be seropositive …
[HTML][HTML] Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …
due to altered antibody evasion properties deriving from their additional spike mutations …
Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age
Background The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part …
coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. Methods Part …
Assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US
Importance COVID-19 was the underlying cause of death for more than 940 000 individuals
in the US, including at least 1289 children and young people (CYP) aged 0 to 19 years, with …
in the US, including at least 1289 children and young people (CYP) aged 0 to 19 years, with …
Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age
Background Since it was first identified in early November 2021, the B. 1.1. 529 (omicron)
variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread …
variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread …
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January …
Summary Background By April 13, 2022, more than 4 months after the approval of
BNT162b2 (Pfizer–BioNTech) for children, less than 40% of 5–11-year-olds in Italy had …
BNT162b2 (Pfizer–BioNTech) for children, less than 40% of 5–11-year-olds in Italy had …
BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age
Background Limited evidence is available on the real-world effectiveness of the BNT162b2
vaccine against coronavirus disease 2019 (Covid-19) and specifically against infection with …
vaccine against coronavirus disease 2019 (Covid-19) and specifically against infection with …
Protection against symptomatic infection with delta (B. 1.617. 2) and omicron (B. 1.1. 529) BA. 1 and BA. 2 SARS-CoV-2 variants after previous infection and …
Background Little is known about protection against SARS-CoV-2 infection following
previous infection with specific individual SARS-CoV-2 variants, COVID-19 vaccination, and …
previous infection with specific individual SARS-CoV-2 variants, COVID-19 vaccination, and …
Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis
Importance Evidence of the efficacy and safety of messenger RNA (mRNA) COVID-19
vaccines in children aged 5 to 11 years has been emerging. Collecting these data will inform …
vaccines in children aged 5 to 11 years has been emerging. Collecting these data will inform …